Medical strategy and tactics

1. Medical strategy and tactics of work in the medical department in the direction of renal cell carcinoma for 2023.

Suleymanova Liliya
2023

2. SWOT analysis

Strengths
SWOT analysis
-The presence of a Cabozantinib on the list of VED
- Recommended as standard of therapy for 1st -line in the
international and Russian clinical guidelines;
-Availability of Cabozantiniba in Clinical Recommendation
RUSSCO :
- first-line therapy
- included in the preference mode in the combination
(Cabo-Niva) for all IMDC risk groups
- included in an alternative regimen in patients with an
intermediate and poor prognosis (monotherapy).
- Combination Cabo-Niva improves PFS and overall survival
(CHECKMATE-9ER) of the SCRR
- Cabo is the treatment of choice for papillary CRR.
- Regional cancer communities aim to create new
organizational approaches for early detection and
personalized treatment of CRR.
- Combination Cabo-Niva has the highest potential for a
future increase in prescriptions for patients in the 1st line of
therapy (according IQVIA, Quantitative market research,
December 2021)
- Kabo as a monotherapy has a good potential for future
growth.
Opportunities
Weaknesses
- Cabozantinib in combination with nivolumab - high degree
of toxicity.
- A lot of adverse events
- The safety and efficacy of Cabozantinib in children have not
been established.
-The diagnosis of RСС is unsatisfactory (more than 50% of
СRR revealed by accident)
- A lot of competitors, a variety of combination therapies
-Sunitinib - a medicine of choice in the regions
- The level of knowledge of oncologists on therapy of
Cabozantinib is the lowest on the 2nd and further lines of
therapy
(IQVIA, Quantitative market research, December 2021)
Threats

3.

Medical strategy:
Raise awareness of scientific leaders by giving the most current scientific
information to inform evidence based decisions in the management of advanced
renal cell carcinoma (RCC) to Improve patient outcomes and Hospital Efficiency.
Medical goals:
Select key oncology hospitals in the Volga and Ural regions and establish a roster of scientific leaders.
Partner with institutions, SLs and scientific societies to establish positive contribution of Ipsen
commitment in the treatment to oncology diseases.
Identify and increase understanding SLs insights on patient profile and also valuate SL insights on
treatment of RCC in real-life clinical practice.
Supporting SLs to facilitate access for the medication.

4. Medical strategy:

Raise awareness of scientific leaders by giving the most current scientific information to
Inform Evidence based decisions in the management of advanced renal cell carcinoma (RCC)
to Improve patient outcomes and Hospital Efficiency.
Medical goal_1:
Select key oncology hospitals in the Volga and Ural regions and establish a roster of
scientific leaders.
Key Tactics
Conducting visits and online meetings with SLs, participating in scientific and
medical-educational events.

5. Medical strategy:

Raise awareness of scientific leaders by giving the most current scientific information to
Inform Evidence based decisions in the management of advanced renal cell carcinoma (RCC)
to Improve patient outcomes and Hospital Efficiency.
Medical goal_2:
Partner with institutions, SLs and scientific societies to establish positive contribution
of Ipsen commitment in the treatment to oncology disease.
Key Tactics:
Scientific exchange with SLs aimed at identifying needs and finding solutions to raise
awareness through visits (live and virtual) and scientific medical educational events;
Initiating and supporting local researches and publications in the field of treatment RCC
that may help close data gaps;
Interactions with patient associations through patient support programs.

6. Medical strategy:

Raise awareness of scientific leaders by giving the most current scientific information to
Inform Evidence based decisions in the management of advanced renal cell carcinoma (RCC)
to Improve patient outcomes and Hospital Efficiency.
Medical goal_3:
Identify and increase understanding SLs insights on patient profile and also valuate SL
insights on treatment of RCC in real-life practice.
Key Tactics:
Advise and secure SLs contribution, to support awareness through symposia and educational activities;
Drive awareness of SLs about patients profile with advanced renal cell carcinoma (RCC) and diseases
management through дальше расписать;
Consider educational activities of scientific regional associations of oncologists;
Identify, communicate and address data gaps;
Develop Medical Education activities and train speakers aligned with planned activities.

7. Medical strategy:

Raise awareness of scientific leaders by giving the most current scientific information to
Inform Evidence based decisions in the management of advanced renal cell carcinoma (RCC)
to Improve patient outcomes and Hospital Efficiency.
Medical goal_3:
Identify and increase understanding SLs insights on patient profile and also valuate SL
insights on treatment of RCC in real-life practice.
Scientific Input:
• Gain insights from scientific leaders on validity, feasibility, and clinical differentiation of Cabozantinib patient profiles in
RCC.
• Gain insights on how institutions identify patients for first-line, 2nd line of therapy and targeted therapy in RCC.
Scientific Exchange:
• Establish the right patient profile for Cabozantinib in RCC from a clinical perspective
• Discuss the clinical importance of Cabozantinib as first-line therapy (in combination), 2nd line therapy and multy
targeted therapy in RCC patients by highlighting its differences from other treatment options.
• Implement data generation: RWE data in patients who received Cabozantinib (characteristics, risk factors, etc);
• Comparative outcomes data that supports the clinical efficacy and safety of Cabozantinib.

8. Medical strategy:

Raise awareness of scientific leaders by giving the most current scientific information to
Inform Evidence based decisions in the management of advanced renal cell carcinoma (RCC)
to Improve patient outcomes and Hospital Efficiency.
Medical goal_4:
Supporting SLs for facilitation of access to the medication
Key Tactics:
Cross-functional interaction and partnership with SF and MA
Collaborations with scientific societies to expedite scientific knowledge into
national guidelines

9. Thank you for attention!